Sodium-glucose transporter type 2 (SGLT2) inhibitors have been shown to confer substantial kidney and cardiovascular benefits among patients with type 2 diabetes, heart failure, and/or high-risk CKD [5, 6]. Here, SLC5A2 is linked to type 2 diabetes mellitus.